Balanced news tone
News Sentiment
AB sentiment intelligence
AB Science S.A. news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
Weighted score
50
Balanced news tone
6 relevant articles
Price is moving more forcefully than the current news tone suggests.
79/100 classification confidence.
directly relevant articles
high-authority source matches
-5.2% over one week, -17.6% over four weeks, trend inactive, and below fair value.
AB Science S.A. Announces Board Changes
Market Reaction
Price moving ahead of tone
Price is moving more forcefully than the current news tone suggests.
Primary event
Market update
79/100 classification
One-week reaction
-5.2%
Price reacting lower
Trend fit
Trend inactive
-17.6% over four weeks
Fair value
-56.0%
Below fair value
Value support
Sentiment Mix
Positive, neutral, negative
Positive
0
Neutral
6
Negative
0
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
Above 50
Neutral zone
Below 50
News Tape
Relevant headlines
marketscreener.com
Direct company coverage
AB Science S.A. Announces Board Changes
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 06 Jul 2026 22:00
- Source
- marketscreener.com
markets.businessinsider.com
Direct company coverage
AB Science patent for masitinib in the treatment of metastatic castrate resistant prostate cancer formally granted in the United States with a protection until 2042
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 17 Jun 2026 07:00
- Source
- markets.businessinsider.com
markets.businessinsider.com
Direct company coverage
AB Science is invited to present at the 2026 ENCALS annual meeting the survival data from masitinib clinical program in ALS
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 09 Jun 2026 07:00
- Source
- markets.businessinsider.com
GlobeNewswire
Direct company coverage
AB Science : Stonegate Capital Partners updates its
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 02 Jun 2026 07:00
- Source
- GlobeNewswire
Market source
Direct company coverage
AB Science announces that its stock continues to be covered by Maxim Group, with a target price of €4.00 per share
- Tone
- Neutral 50/100
- Event
- Analyst action
- Published
- 25 May 2026 07:00
- Source
- Market source
Market source
Direct company coverage
AB Science: New publication on medrxiv demonstrating substantial survival benefits and preserved quality of life with masitinib in ALS patients
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 20 Apr 2026 07:00
- Source
- Market source